Vascular adhesion protein‐1 (VAP‐1) is one of the endothelial adhesion molecules that is believed to play a role in tumor progression and metastasis, supporting cancer cell extravasation. Very few studies have been performed on analyzing the contribution of VAP‐1 in brain tumor. Astrocytomas are the most common type of brain tumors, which are classified by World Health Organization (WHO) into four grades according to the degree of malignancy. This study was designed to investigate VAP‐1 expression level in different astrocytoma grades and its correlation with clinicopathological features as well as prognosis of astrocytoma patients. Eighty‐seven patients with different grades of astrocytoma (WHO Grade I–Grade IV) were enrolled in this study. The expression of VAP‐1 was assayed by immunohistochemistry. The correlation between VAP‐1 expression and clinicopathological features was evaluated by Chi‐square test, and overall survival was analyzed by Kaplan–Meier method. Cox regression analysis was applied to analyze the independent influence of each parameter on overall survival. The expression level of VAP‐1 was significantly higher in diffuse astrocytoma than those of pilocytic astrocytoma (p < 0.0001). In the subgroup analysis, upregulated VAP‐1 expression was frequently found in older age patients (≥50 years). The VAP‐1 expression was found to be significantly correlated with the overall survival (p = 0.0002). There was a statistical correlation between VAP‐1high tumors in diffuse astrocytoma and VAP‐1low tumors in pilocytic astrocytoma (p < 0.0001). Multivariate Cox analysis indicated VAP‐1 was an independent predictive marker for poorer prognosis (p = 0.0036). Therefore, VAP‐1 could be a promising prognostic biomarker in astrocytoma.